IL278844A - Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and their uses - Google Patents
Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and their usesInfo
- Publication number
- IL278844A IL278844A IL278844A IL27884420A IL278844A IL 278844 A IL278844 A IL 278844A IL 278844 A IL278844 A IL 278844A IL 27884420 A IL27884420 A IL 27884420A IL 278844 A IL278844 A IL 278844A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- bispecific antibodies
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676123P | 2018-05-24 | 2018-05-24 | |
| US201962825846P | 2019-03-29 | 2019-03-29 | |
| PCT/IB2019/054182 WO2019224711A2 (en) | 2018-05-24 | 2019-05-21 | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL278844A true IL278844A (en) | 2021-01-31 |
Family
ID=67211770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278844A IL278844A (en) | 2018-05-24 | 2020-11-19 | Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and their uses |
Country Status (23)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1253512A1 (zh) | 2015-05-29 | 2019-06-21 | Amphivena Therapeutics, Inc. | 双特异性cd33和cd3结合蛋白质的使用方法 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| BR112020023508A2 (pt) | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| AR119259A1 (es) | 2018-08-31 | 2021-12-09 | Alector Llc | Anticuerpos anti-cd33 y métodos de uso de los mismos |
| DE102018127845A1 (de) | 2018-11-07 | 2020-05-07 | Grimme Landmaschinenfabrik Gmbh & Co. Kg | Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten |
| AU2020225631A1 (en) | 2019-02-22 | 2021-09-16 | Memorial Sloan Kettering Cancer Center | CD33 antibodies and methods of using the same to treat cancer |
| CA3131689A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| JP7686571B2 (ja) | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク,インコーポレーテツド | T細胞媒介性免疫を調節するための材料及び方法 |
| AU2020400030B2 (en) | 2019-12-09 | 2026-05-21 | Twist Bioscience Corporation | Variant nucleic acid libraries for adenosine receptors |
| CA3173268A1 (en) * | 2020-02-27 | 2021-09-02 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| WO2021183845A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Materials and methods for modulating delta chain mediated immunity |
| PE20231517A1 (es) * | 2020-03-13 | 2023-09-28 | Janssen Biotech Inc | Materiales y metodos para la union de siglec-3/cd33 |
| CN113461817B (zh) * | 2020-03-31 | 2025-04-18 | 苏州泽璟生物制药股份有限公司 | 一种抗人cd47抗体及其抗原结合片段、制备方法和应用 |
| EP4126925A4 (en) * | 2020-03-31 | 2024-07-24 | Fred Hutchinson Cancer Center | CHIMERIC ANTIGEN RECEPTORS TARGETED AGAINST CD33 |
| CA3173213A1 (en) * | 2020-03-31 | 2021-10-07 | Roland B. WALTER | Anti-cd33 antibodies and uses thereof |
| JP7840865B2 (ja) | 2020-03-31 | 2026-04-06 | フレッド ハッチンソン キャンサー センター | キメラ抗原受容体ターゲティングcd33 |
| EP4126248A4 (en) | 2020-03-31 | 2024-07-10 | Fred Hutchinson Cancer Center | HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES |
| WO2021231237A2 (en) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
| PE20230389A1 (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| WO2022159620A1 (en) * | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| CA3214594A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Trispecific antibody targeting cd79b, cd20, and cd3 |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| CN117715935A (zh) * | 2021-07-30 | 2024-03-15 | 南京传奇生物科技有限公司 | 抗cd33抗体及其用途 |
| EP4396235A4 (en) * | 2021-09-02 | 2025-07-02 | Memorial Sloan Kettering Cancer Center | ANTI-CD33 ANTIBODIES AND THEIR USES |
| KR20240055002A (ko) * | 2021-09-13 | 2024-04-26 | 얀센 바이오테크 인코포레이티드 | 암 치료를 위한 CD33 x Vδ2 다중특이성 항체 |
| WO2023081898A1 (en) * | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| JP2026502768A (ja) * | 2022-10-25 | 2026-01-27 | アブレクシス, エルエルシー | 抗cd3抗体 |
| AR134580A1 (es) * | 2023-12-08 | 2026-01-28 | Janssen Biotech Inc | ANTICUERPOS DE CD33, ANTICUERPOS MULTIESPECÍFICOS DE CD33 / Vd2 Y USOS DE ESTOS |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025174974A1 (en) * | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| CN118221826B (zh) * | 2024-04-25 | 2024-11-15 | 北京绿竹生物技术股份有限公司 | 一种结合人cd33和cd3的双特异性抗体 |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| CN119804863B (zh) * | 2025-03-13 | 2025-06-17 | 北京华诺泰生物医药科技有限公司 | 检测人偏肺病毒抗原的酶联免疫试剂盒及定量检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| MX2011003502A (es) | 2008-10-01 | 2011-09-01 | Micromet Ag | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| AR098743A1 (es) | 2013-12-13 | 2016-06-08 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| DK3189081T3 (da) * | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| AU2016276981B2 (en) * | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| EP3307779A2 (en) * | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| MY205541A (en) | 2017-08-03 | 2024-10-25 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EA202091976A1 (ru) | 2018-02-20 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на cd33, и их применение |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
-
2018
- 2018-05-24 JO JOP/2019/0116A patent/JOP20190116A1/ar unknown
-
2019
- 2019-05-21 PE PE2020001885A patent/PE20210180A1/es unknown
- 2019-05-21 WO PCT/IB2019/054182 patent/WO2019224711A2/en not_active Ceased
- 2019-05-21 MX MX2020012588A patent/MX2020012588A/es unknown
- 2019-05-21 CR CR20200567A patent/CR20200567A/es unknown
- 2019-05-21 MA MA052771A patent/MA52771A/fr unknown
- 2019-05-21 EP EP19737216.2A patent/EP3802606B1/en active Active
- 2019-05-21 BR BR112020023357-9A patent/BR112020023357A2/pt unknown
- 2019-05-21 ES ES19737216T patent/ES2998890T3/es active Active
- 2019-05-21 AU AU2019274229A patent/AU2019274229B2/en active Active
- 2019-05-21 JP JP2020564908A patent/JP7530298B2/ja active Active
- 2019-05-21 CN CN201980034952.6A patent/CN112189022B/zh active Active
- 2019-05-21 KR KR1020207036865A patent/KR102890653B1/ko active Active
- 2019-05-21 US US16/418,420 patent/US11466082B2/en active Active
- 2019-05-21 SG SG11202011210TA patent/SG11202011210TA/en unknown
- 2019-05-23 TW TW108117806A patent/TW202033551A/zh unknown
- 2019-05-24 UY UY0001038242A patent/UY38242A/es unknown
-
2020
- 2020-11-19 IL IL278844A patent/IL278844A/en unknown
- 2020-11-20 CL CL2020003028A patent/CL2020003028A1/es unknown
- 2020-11-23 NI NI202000088A patent/NI202000088A/es unknown
- 2020-11-23 PH PH12020552010A patent/PH12020552010A1/en unknown
- 2020-11-23 EC ECSENADI202075198A patent/ECSP20075198A/es unknown
- 2020-11-24 CO CONC2020/0014575A patent/CO2020014575A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019224711A2 (en) | 2019-11-28 |
| MA52771A (fr) | 2021-04-14 |
| EP3802606A2 (en) | 2021-04-14 |
| ES2998890T3 (en) | 2025-02-24 |
| US20190382481A1 (en) | 2019-12-19 |
| KR102890653B1 (ko) | 2025-11-24 |
| CA3101270A1 (en) | 2019-11-28 |
| WO2019224711A3 (en) | 2020-01-02 |
| CN112189022A (zh) | 2021-01-05 |
| SG11202011210TA (en) | 2020-12-30 |
| PE20210180A1 (es) | 2021-01-29 |
| CL2020003028A1 (es) | 2021-04-16 |
| US11466082B2 (en) | 2022-10-11 |
| PH12020552010A1 (en) | 2021-06-14 |
| UY38242A (es) | 2019-11-29 |
| JP2021524244A (ja) | 2021-09-13 |
| KR20210013156A (ko) | 2021-02-03 |
| CN112189022B (zh) | 2025-04-15 |
| TW202033551A (zh) | 2020-09-16 |
| BR112020023357A2 (pt) | 2021-04-27 |
| NI202000088A (es) | 2021-03-23 |
| AU2019274229A1 (en) | 2020-11-26 |
| EP3802606B1 (en) | 2024-10-09 |
| JP7530298B2 (ja) | 2024-08-07 |
| ECSP20075198A (es) | 2020-12-31 |
| AU2019274229B2 (en) | 2026-03-19 |
| JOP20190116A1 (ar) | 2019-11-24 |
| MX2020012588A (es) | 2021-04-28 |
| CR20200567A (es) | 2021-01-20 |
| CO2020014575A2 (es) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202011210TA (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| HUS2500032I1 (hu) | Bispecifikus anti-BCMA X anti-CD3 antitestek és azok alkalmazásai | |
| IL283493A (en) | Anti-muc16 and anti-cd28 bispecific antibodies and their uses | |
| IL273871A (en) | ANTI-CD38 antibodies and combinations with ANTI-CD3 and ANTI-CD28 antibodies | |
| IL278846A (en) | Anti-CD3 antibodies and uses thereof | |
| IL283945A (en) | Anti-cd28 and anti-cd22 bispecific antibodies and their uses | |
| IL279354A (en) | Bispecific antibodies against PSMA and against CD28 and their uses | |
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| IL283530A (en) | Bispecific anti-pd-l1/anti-4-1bb antibodies and their uses | |
| IL258036A (en) | Optimized bispecific antibodies against class 3 determinants and their uses | |
| EP3527590A4 (en) | SPECIFIC ANTI-EGFR AND ANTI-CD3 ANTIBODIES AND APPLICATIONS THEREOF | |
| AU2016210068A1 (en) | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 | |
| GB201710838D0 (en) | Bispecific antibodies | |
| EP3661555C0 (en) | BISPECIFIC ANTIBODIES AND THEIR USES | |
| PL3797121T3 (pl) | Przeciwciała swoiste dla CD3 i ich zastosowania | |
| IL271128A (en) | New anti-3cd antibodies | |
| SG11202011268VA (en) | Monospecific and multispecific anti-tmeff2 antibodies and there uses | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| IL269577B (en) | Bispecific antibodies anti–pd–l1–anti–tim–3 | |
| PT3802598T (pt) | Proteínas de ligação dll3/cd3 para tratamento de cancro | |
| HK40025714A (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
| HK40023842A (en) | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof | |
| HK1239720B (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| HK1239720A1 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |